Semaglutide Oral vs Mazdutide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Rybelsus
Oral semaglutide is the pill version of the same GLP-1 peptide found in Ozempic and Wegovy, sold for type 2 diabetes as Rybelsus. The trick that makes it work is an absorption enhancer called SNAC, which shields the peptide from stomach acid and helps it cross the gut lining. Lower doses are approved for diabetes, and higher 25 mg doses have now been approved as the first GLP-1 pill for weight loss.
Also: IBI362, LY3305677
Mazdutide is a GLP-1 and glucagon dual agonist, which puts it between semaglutide (GLP-1 only) and retatrutide (GLP-1, GIP and glucagon). It is built on oxyntomodulin, a natural gut hormone that hits both receptors, rather than on a GLP-1 backbone. It is furthest along in China, where it is approved for both weight management and type 2 diabetes. Western approval has not happened.
Key Comparison Insights
- Semaglutide Oral is FDA approved, while Mazdutide remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Semaglutide Oral has stronger research evidence (FDA Approved) compared to Mazdutide (Human Trials).
Detailed Comparison
| Attribute | Semaglutide Oral | Mazdutide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | The active drug is identical semaglutide, a GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and boosts glucose-dependent insulin release. The hard part is getting a delicate peptide through the stomach intact, because enzymes there normally destroy it. Each tablet co-formulates semaglutide with SNAC (sodium N-(8-[2-hydroxybenzoyl]amino) caprylate), which raises the local pH around the tablet, protects the peptide from breakdown, and helps it slip across the gastric lining into the blood. That is also why the pill must be taken on an empty stomach with a small sip of water and then nothing else for about 30 minutes, since food and extra fluid wreck absorption. | Two receptors, two jobs. The GLP-1 arm does the familiar work: it suppresses appetite, slows gastric emptying and improves glucose-dependent insulin release. The glucagon arm is the interesting half, because glucagon is normally thought of as the hormone that raises blood sugar. At these doses the intent is to exploit glucagon's other effects, increasing energy expenditure and pushing the liver to burn fat, while the GLP-1 arm keeps blood glucose in check and cancels out glucagon's hyperglycemic tendency. That balance is the whole design: glucagon supplies extra fat burning that GLP-1 alone cannot, and GLP-1 supplies the safety margin that makes adding glucagon viable. Reported reductions in liver fat are consistent with the glucagon component doing what it is meant to. |
| Common Dosing | Limited community data available See research protocols | 4-6 mg weekly Once weekly |
| Administration | Oral tablet on empty stomach with <4oz water | Subcutaneous injection, once weekly |
| Typical Duration | Long-term / chronic use | Ongoing weekly use in trials, typically assessed at 24 to 48 weeks |
| Best Time to Take | Before bed or morning (fasted) | Same day each week, morning preferred |
Possible Side Effects May vary by individual |
|
|
| Research Summary | This is well-studied with large, published human trials, not preliminary work. The PIONEER program enrolled over 9,500 people with type 2 diabetes and showed oral semaglutide lowered A1C by roughly 0.6 to 1.4 percentage points and produced modest weight loss, generally matching or beating comparators like sitagliptin and empagliflozin. PIONEER PLUS, published in The Lancet, tested higher 25 mg and 50 mg doses and found greater A1C and weight reductions than the standard 14 mg. For obesity specifically, the OASIS trials moved to higher doses: OASIS 1 showed about 15.1% weight loss on 50 mg versus 2.4% on placebo, and OASIS 4 (NEJM, 2025) showed roughly 13.6% loss at 64 weeks on 25 mg, comparable to the injectable Wegovy dose. Side effects are the usual GLP-1 GI complaints. The honest tradeoff: it is real and effective, but absorption is finicky and the strict empty-stomach dosing rule matters more than people expect. | The pivotal trial is GLORY-1, published in the New England Journal of Medicine in 2025: 610 Chinese adults with overweight or obesity over 48 weeks. Mean weight reduction was 11.0 percent at 4 mg and 14.0 percent at 6 mg, alongside improvements in liver fat, blood pressure and lipids. A 9 mg dose has since been studied in phase 2 (about 12.8 percent at 24 weeks) and is in phase 3. Tolerability followed the pattern of the whole class, dominated by dose-dependent nausea, vomiting and diarrhea during titration. One caveat matters when reading these numbers: GLORY-1 enrolled a population with a mean BMI of 31.1, against roughly 38 in the Western trials of semaglutide and tirzepatide, so the percentages are not directly comparable to SURMOUNT-1 or STEP-1 results. There is no completed Western phase 3 program, so neither the FDA nor the EMA has assessed it, and meaningful head-to-head data against tirzepatide or retatrutide does not exist. |
Frequently Asked Questions: Semaglutide Oral vs Mazdutide
What is the difference between Semaglutide Oral and Mazdutide?
Semaglutide Oral is a weight loss peptide that oral semaglutide is the pill version of the same glp-1 peptide found in ozempic and wegovy, sold for type 2 diabetes as rybelsus. the trick that makes it work is an absorption enhancer called snac, which shields the peptide from stomach acid and helps it cross the gut lining. lower doses are approved for diabetes, and higher 25 mg doses have now been approved as the first glp-1 pill for weight loss. Mazdutide is a weight loss peptide that mazdutide is a glp-1 and glucagon dual agonist, which puts it between semaglutide (glp-1 only) and retatrutide (glp-1, gip and glucagon). it is built on oxyntomodulin, a natural gut hormone that hits both receptors, rather than on a glp-1 backbone. it is furthest along in china, where it is approved for both weight management and type 2 diabetes. western approval has not happened. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Semaglutide Oral or Mazdutide?
Neither is universally "better" - the choice depends on your specific goals. Semaglutide Oral is typically used for weight loss purposes, while Mazdutide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Semaglutide Oral and Mazdutide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Semaglutide Oral and Mazdutide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.